US Stock Insider Trading | Wanjie Genetics Disclosed One Insider Transaction on March 9

K-LinePoet · 2026-03-16T10:35:21+00:00

On March 9, 2026, Wanji Genetics director Raha Samraat S. bought 40,000 shares, indicating active insider trading. Recent transactions by executives and directors also include both sales and purchases, reflecting shareholders' concern about market trends. Myriad Genetics specializes in genetic testing and precision medicine, dedicated to improving health and supporting treatment decisions.

K-LinePoet

2026-03-16 10:35:21

Abstract generation in progress

On March 9, 2026, Myriad Genetics (MYGN) disclosed one insider transaction. Director Raha Samraat S. purchased 40,000 shares.

[Recent Insider Transactions]

Disclosure Date	Position	Name	Transaction Date	Buy/Sell	Quantity	Price per Share/USD	Total Amount/USD
March 9, 2026	Director	Raha Samraat S.	March 9, 2026	Buy	40,000	5.00	199,800
March 2, 2026	Executive	Solaiman Shereen	March 1, 2026	Sell	1,675	4.61	7,721.75
February 27, 2026	Director	Phanstiel S. Louise	February 26, 2026	Buy	50,400	4.80	242,100
February 27, 2026	Director	Phanstiel S. Louise	February 25, 2026	Buy	6,100	4.74	28,900
February 27, 2026	Director	Phanstiel S. Louise	February 27, 2026	Buy	48,000	4.66	223,700
January 2, 2026	Executive	Muzzey Dale	January 1, 2026	Sell	418	6.15	2,570.70
December 29, 2025	Executive	Wheeler Benjamin Richard	December 25, 2025	Sell	21	6.55	137.55
December 12, 2025	Director	Raha Samraat S.	December 11, 2025	Sell	29,600	7.30	216,300
September 22, 2025	Executive	Wheeler Benjamin Richard	September 21, 2025	Sell	2,559	7.77	19,900
September 22, 2025	Executive	Munk Natalie	September 21, 2025	Sell	962	7.77	7,474.74

[Company Information]

Myriad Genetics, Inc. is a Delaware corporation. The company is a leading gene testing and precision medicine company dedicated to promoting health and well-being for all. Its insights help people take control of their health and enable healthcare providers to better detect, treat, and prevent diseases. The company develops and offers tests to assess the risk of disease or disease progression and guides treatment decisions across medical disciplines, where genetic insights can significantly improve patient care and reduce healthcare costs.

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.